Next Science Earnings Estimate
Next Science Earnings per Share Projection vs Actual
About Next Science Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Next Science earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Next Science estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Next Science fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. Next Science Limited was founded in 2012 and is headquartered in Chatswood, Australia. Next Science operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Next Pink Sheet
Next Science financial ratios help investors to determine whether Next Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Next with respect to the benefits of owning Next Science security.